U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06911866) titled 'A Phase Ib Study of RC1416 Injection' on March 28.
Brief Summary: This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RC1416 injection in patients with moderate to severe asthma.
Study Start Date: May 25
Study Type: INTERVENTIONAL
Condition:
Moderate to Severe Asthma
Intervention:
DRUG: RC1416
there are four doses(200mg-400mg) in this part. Each subjects will receive the drug once by subcutaneous injection.
DRUG: RC1416 Placebo
Each subjects will receive the placebo once by subcutaneous injection.
Recruitment Status: NOT_YET_RECRUITIN...